We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

7 hedge funds and large institutions have $845K invested in Alexion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 693 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

99% less funds holding

Funds holding: 707 → 7 (-700)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 693

100% less funds holding in top 10

Funds holding in top 10: 77 → 0 (-77)

100% less capital invested

Capital invested by funds: $38.8B → $845K (-$38.8B)

Holders
7
Holders Change
-700
Holders Change %
-99.01%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
-77
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
693
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NICM
Neo Ivy Capital Management
New York
+$475K
2
TAIM
TD Ameritrade Investment Management
Nebraska
+$131K
3
RG
Retirement Group
California
+$9.37K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$3.74B
2
BlackRock
BlackRock
New York
-$3.21B
3
State Street
State Street
Massachusetts
-$1.84B
4
FCM
Farallon Capital Management
California
-$1.42B
5
HI
HBK Investments
Texas
-$1.21B
Name Holding Trade Value Shares
Change 		Change in
Stake
FL
376
Fort LP
Maryland
– -$1.44M -7,813 Closed
PSP
377
Principal Street Partners
Tennessee
– -$1.43M -7,804 Closed
CAN
378
Cetera Advisor Networks
California
– -$1.43M -7,761 Closed
AIP
379
Ameritas Investment Partners
Nebraska
– -$1.43M -7,757 Closed
OAM
380
Origin Asset Management
United Kingdom
– -$1.42M -7,700 Closed
DBG
381
De Burlo Group
Massachusetts
– -$1.4M -7,625 Closed
AFA
382
Abacus FCF Advisors
Florida
– -$1.38M -7,565 Closed
AAM
383
Advisors Asset Management
Colorado
– -$1.35M -7,361 Closed
PAM
384
Panagora Asset Management
Massachusetts
– -$1.34M -7,318 Closed
CWAF
385
Core Wealth Advisors (Florida)
Florida
– -$1.33M -7,238 Closed
ECM
386
Everence Capital Management
Indiana
– -$1.3M -7,091 Closed
GD
387
Grandfield & Dodd
New York
– -$1.29M -7,016 Closed
CI
388
Cigna Investments
Connecticut
– -$1.28M -6,971 Closed
EF
389
Empirical Finance
Pennsylvania
– -$1.25M -6,828 Closed
OPPTF
390
OPSEU Pension Plan Trust Fund
Ontario, Canada
– -$1.26M -6,775 Closed
OFA
391
Oak Family Advisors
Illinois
– -$1.23M -6,706 Closed
RIM
392
Redpoint Investment Management
Australia
– -$1.23M -6,684 Closed
BMSSC
393
B. Metzler seel. Sohn & Co
Germany
– -$1.18M -6,425 Closed
VF
394
Virtu Financial
New York
– -$1.17M -6,356 Closed
HVM
395
Harvest Volatility Management
Connecticut
– -$1.16M -6,336 Closed
Wealthfront Advisers
396
Wealthfront Advisers
California
– -$1.15M -6,269 Closed
IRF
397
IBM Retirement Fund
New York
– -$1.14M -6,225 Closed
CP
398
Camelot Portfolios
Ohio
– -$1.14M -6,212 Closed
HSA
399
Hussman Strategic Advisors
Maryland
– -$1.14M -6,200 Closed
AA
400
ALPS Advisors
Colorado
– -$1.12M -6,087 Closed
14 15
16
17 18

ALXN Hedge Fund Activity: Q3 2021 in Review

7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2021, worth a combined $845K — down 100% from $38.8B a quarter earlier.

Sellers outnumbered buyers: 693 funds closed out of ALXN and 1 opened new positions — a net loss of 692 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $475K. The largest seller was Vanguard Group, exiting entirely with an estimated $3.74B sold.

  • 7 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2021, down from 707 in Q2 2021.
  • Funds reported $845K of Alexion Pharmaceuticals stock for Q3 2021, down 100% quarter-over-quarter.
  • 1 fund opened new Alexion Pharmaceuticals positions in Q3 2021 and 693 closed out, a net change of -692 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $475K added.
  • The largest Alexion Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $3.74B sold.

Based on aggregated 13F filings for Q3 2021.